Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
HIV, Salivary Gland Disease, Benign Lymphoepithelial Lesion
Interventions
Ciprofloxacin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Conditions
Human Immunodeficiency Virus
Interventions
brentuximab vedotin, Placebo, ART
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Completed Phase 1 Interventional Accepts healthy volunteers

Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng

NCT01755741
Conditions
Human Immunodeficiency Virus
Interventions
Placebo Vaginal Ring, Condom
Combination Product · Device
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Berkeley, California • Los Angeles, California
Completed Phase 1Phase 2 Interventional Results available

Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease

NCT01058941
Conditions
Alzheimer's Disease
Interventions
Lipoic acid and fish oil concentrate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Terminated Phase 2 Interventional Results available

Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

NCT00670202
Conditions
Carotid Stenosis
Interventions
Fasudil Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV, Cardiovascular Diseases, Atherosclerosis
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

NCT04078022
Conditions
Shigella
Interventions
SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions
Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
Drug · Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Urethral Analgesia on Voiding

NCT02823431
Conditions
Urethral Analgesia
Interventions
lidocaine gel, Plain aqueous gel
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Results available

Duration of Effect of Biotene Spray in Patients With Dry Mouth

NCT03663231
Conditions
Dry Mouth
Interventions
Biotene, Placebo
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, New York
Conditions
Painful Diabetic Neuropathies
Interventions
Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more
Conditions
Myasthenia Gravis
Interventions
Tolebrutininb, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Boca Raton, Florida • Tampa, Florida + 2 more
Conditions
Obesity
Interventions
NT-0796, Placebo
Drug
Lead sponsor
Rezera (formerly NodThera Limited)
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Mesa, Arizona • Hialeah, Florida • Jacksonville, Florida + 6 more
Conditions
HCMV Reactivation or HCMV End-Organ Disease
Interventions
60 mg AIC246, 120 mg AIC246, 240 mg AIC246, Placebo
Drug · Other
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Conditions
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Interventions
Amlitelimab, BI 1015550 (Nerandomilast), Placebo
Drug
Lead sponsor
Scleroderma Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Conditions
SARS-CoV-2 Infection
Interventions
PF-07817883, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
53
States / cities
Cullman, Alabama • Phoenix, Arizona • Surprise, Arizona + 45 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

NCT02066792
Conditions
Social Anxiety Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Austin, Texas
Conditions
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
18
States / cities
Little Rock, Arkansas • Anaheim, California • Berkeley, California + 15 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Does Montelukast Decrease Post Adenotonsillectomy Pain in Children

NCT02793375
Conditions
Pain
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 8 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Pediatric Lower Limb Spasticity

NCT01603628
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 16 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
24
States / cities
Pasadena, California • Pomona, California • Aurora, Colorado + 19 more
Conditions
Cervical Spondylotic Myelopathy
Interventions
riluzole, Placebo medication
Drug
Lead sponsor
AOSpine North America Research Network
Network
Eligibility
18 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 11 more
Conditions
Cataract
Interventions
Nepafenac 0.3% Oph Susp, Placebos, Nepafenac 0.3% Oph Susp (reference)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas